Jump to content
  • Rosacea Research

    microscope.jpgrrdiLogo384x64.jpg.3cd1bd79f5d066075bdd9

    Rosacea Research

    Rosaceans can make a difference in rosacea research by joining the RRDi as a corporate member. Please join and VOLUNTEER

    The RRDi could engage in some novel rosacea research. You can become involved with this volunteer movement of rosaceans making a difference in the direction of rosacea research. Never underestimate the power of rosaceans volunteering. For example, you could volunteer as a grant writer (if you have no experience you could learn how). If you are a professional grant writer, or would like to learn how to write grants for rosacea research, please click here.

    Joel T. Bamford, M.D., wrote an article in the Journal of the RRDi entitled, "Is it possible for rosaceans to do research?" The answer to that question is joining our cause and making this possible. The RRDi is in the forefront of the medical digital revolution which you can be a part of. For more information click here.

    "However, as another important outcome, their analyses also highlighted the need for better-quality studies evaluating treatments for rosacea....The reviewers also found there were no randomized, controlled trials evaluating other treatments commonly used for rosacea, including doxycycline, minocycline, isotretinoin, laser therapy, erythromycin, dapsone and topical tretinoin." [1]

    According to Michael Detmar, M.D., in 2003, only one paper was published for every 144,000 rosacea patients in the United States, compared to a 1-to-11 ratio for melanoma and 1 to 4,900 for psoriasis. [Source]

    sci_w_tube.jpg

    RRDi Education Grants

    The RRDi has funded educational grants sponsored by Galderma. For more information click here.

    Volunteer

    If you want to become involved as a volunteer you can begin to educate yourself with the following subjects on rosacea research:

    Rosacea Research in Perspective of Idiopathic Diseases

    Rosacea Research in Perspective of Funding

    Rosacea Research Forum

    Rosacea RRDi Research Articles

    Call For Papers - Journal of the RRDi. Volume 2, No. 1

    Rosaceans Funding Rosacea Research
    Could 10K members of the RRDi get together and each donated one dollar and fund a double blind, placebo controlled, peer reviewed clinical study research paper on rosacea? Only if you become involved. That is what volunteering is all about. Donate.

    End Notes

    [1] Rosacea Treatment Studies Scrutinized by Reviewers
    Better-quality assessments essential to evaluate treatments, analysis shows
    Dermatology Times, Publish date: Feb 1, 2005 By: Cheryl Guttman



  • Posts

    • Cornea. 2024 Jul 5. doi: 10.1097/ICO.0000000000003627. Online ahead of print. ABSTRACT PURPOSE: The purpose of this study was to report the outcomes of quantum molecular resonance (QMR) electrotherapy in the management of refractory pediatric ocular rosacea. METHODS: This is a retrospective case series on 3 female pediatric patients (ages 12, 15, 14 years) with ocular rosacea. Two patients presented with corneal stromal neovascularization and punctate epithelial erosions while 1 patient presented with corneal scarring and paracentral stromal thinning. After failing conservative management, the patients were treated with 4 consecutive QMR electrotherapy sessions with the intensity set at 5 corresponding on average to a power of 12 W, with 60 V voltage and 200 mA current. Informed consent was obtained for off-label use. Patients were assessed for changes in vision, foreign body sensation, tearing, photophobia, and redness at each visit to determine symptomatic improvement. Outcome measures include best-corrected visual acuity, use of supplemental therapies (eg topical steroids) for symptom relief, extent of corneal neovascularization via serial slitlamp photography, and corneal scar remodeling via high resolution anterior segment optical coherence tomography (OCT). RESULTS: Two of the 3 patients experienced improvement in visual acuity after QMR electrotherapy. Corneal neovascularization and scarring regressed significantly in all 3 patients. Two months post-QMR electrotherapy, corneal remodeling was evident on optical coherence tomography in 2 patients. All 3 patients were able to discontinue topical immunosuppressants and remain symptom-free at 1.5 years of follow-up. CONCLUSIONS: QMR electrotherapy is a promising alternative in the treatment of refractory ocular rosacea in childhood and puberty, and it may potentiate corneal remodeling. PMID:38967538 | DOI:10.1097/ICO.0000000000003627 {url} = URL to article
    • J Alzheimers Dis. 2024 Jun 28. doi: 10.3233/JAD-240198. Online ahead of print. ABSTRACT This manuscript reviews the significant skin manifestations of Lewy body disease, including Parkinson's disease and dementia with Lewy bodies, and the diagnostic utility of skin biopsy. Besides classic motor and cognitive symptoms, non-motor manifestations, particularly dermatologic disorders, can play a crucial role in disease presentation and diagnosis. This review explores the intricate relationship between the skin and Lewy body disease. Seborrheic dermatitis, autoimmune blistering diseases (bullous pemphigoid and pemphigus), rosacea, and melanoma are scrutinized for their unique associations with Parkinson's disease, revealing potential links through shared pathophysiological mechanisms. Advances in diagnostic techniques allow the identification of promising biomarkers such as α-synuclein in samples obtained by skin punch biopsy. Understanding the dermatologic aspects of Lewy body disease not only contributes to its holistic characterization but also holds implications for innovative diagnostic approaches. PMID:38968048 | DOI:10.3233/JAD-240198 {url} = URL to article
    • JAAD Int. 2024 May 6;16:112-118. doi: 10.1016/j.jdin.2024.04.009. eCollection 2024 Sep. ABSTRACT PMID:38957837 | PMC:PMC11217679 | DOI:10.1016/j.jdin.2024.04.009 {url} = URL to article
    • Clin Cosmet Investig Dermatol. 2024 Jun 26;17:1551-1552. doi: 10.2147/CCID.S484236. eCollection 2024. ABSTRACT [This corrects the article DOI: 10.2147/CCID.S473598.]. PMID:38952412 | PMC:PMC11215658 | DOI:10.2147/CCID.S484236 {url} = URL to article
    • Heliyon. 2024 Jun 1;10(11):e32275. doi: 10.1016/j.heliyon.2024.e32275. eCollection 2024 Jun 15. ABSTRACT A combination of benzoyl peroxide (BPO) and tretinoin is recommended for treating acne; however, concurrent administration can be irritating, and coformulation is prevented by BPO-mediated oxidation of tretinoin. In rosacea, benzoyl peroxide has been shown to be efficacious; however, its use has been limited by poor tolerability. To overcome these limitations, the active ingredients can be encapsulated within silica microcapsules. The US Food and Drug Administration has approved 2 products using this technology, a combination of encapsulated benzoyl peroxide and encapsulated tretinoin product for acne vulgaris and encapsulated benzoyl peroxide to treat inflammatory lesions in rosacea. The active ingredients are released through small channels in the silica shell, gradually releasing the active ingredients to the skin. This study describes the stability and release profiles of encapsulated tretinoin and encapsulated benzoyl peroxide from the silica shell in physiologically relevant conditions and provides differentiation from traditional formulations. PMID:38947450 | PMC:PMC11214359 | DOI:10.1016/j.heliyon.2024.e32275 {url} = URL to article
×
×
  • Create New...

Important Information

Terms of Use